KCL Capital’s Stoke Therapeutics STOK Stock Holding History

KCL Capital’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,000	Closed	-$292K	–	51
2019 Q2	$292K	Buy	+10,000	New	+$269K	0.03%	35

Other funds holding STOK

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCL Capital's STOK Position: Q3 2019 in Review

KCL Capital sold out of Stoke Therapeutics (STOK) in Q3 2019, closing a stake of 10,000 shares — an estimated $292K sold.

KCL Capital first reported a position in STOK in Q2 2019 and held it in 1 quarter. The position peaked at $292K in Q2 2019. 53 funds tracked by Wall St. Rank hold STOK as of Q3 2019.

KCL Capital reported no remaining Stoke Therapeutics position as of Q3 2019 after selling out during the quarter.
KCL Capital sold 10,000 Stoke Therapeutics shares in Q3 2019, an estimated $292K.
KCL Capital first reported a position in Stoke Therapeutics in Q2 2019 and held it in 1 quarter.
KCL Capital's Stoke Therapeutics position peaked at $292K in Q2 2019.
53 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2019.

Based on KCL Capital's 13F filing for Q3 2019, filed 14 Nov 2019.